# CJC-1295 Ipamorelin as a Growth Hormone Secretagogue

> How CJC-1295 Ipamorelin works as a growth hormone secretagogue — the GHRH and ghrelin-receptor arms, the selective ipamorelin profile, and the class safety signal, each cited to the literature.

What the term means, which arm each peptide occupies, and why ipamorelin earned the word 'selective.'

## In plain English

A **growth hormone secretagogue** is anything that makes the body release more of its own growth hormone, rather than supplying growth hormone from outside. The CJC-1295 Ipamorelin pairing is a secretagogue approach in this exact sense: it does not add growth hormone, it coaxes the pituitary gland to make more. It does this through two different controls. CJC-1295 works the GHRH control — the natural "make growth hormone" signal — and is built to keep working for days. Ipamorelin works a second control, the ghrelin receptor, the same switch the hunger hormone uses, and it does so unusually cleanly: it releases growth hormone without setting off the stress hormones that older peptides in its class disturbed. This page explains what each arm does, why the combination is described as supra-additive (greater than the sum of its parts), and what the class-wide safety picture looks like. As elsewhere on this site, the blend itself has no trial — the evidence is single-component and general.

## What the term means

In endocrinology, a *secretagogue* is an agent that triggers secretion. A **growth hormone secretagogue** triggers the pituitary's own GH release. The category divides by mechanism: GHRH analogues act on the GHRH receptor (a class-B GPCR that raises cAMP), while GHRPs — growth-hormone-releasing peptides — act on the ghrelin receptor, GHS-R1a (which raises intracellular calcium). CJC-1295 is the GHRH-analogue type; ipamorelin is the GHRP type. Because the two receptors sit on the same somatotroph cell yet signal through independent pathways, an agent from each category can be combined for a larger effect than either produces alone [3] [4].

## The two arms in detail

The GHRH arm — CJC-1295 — binds the GHRH receptor and drives GH synthesis and release; its DAC form binds albumin for a multi-day half-life, sustaining GH and IGF-1 elevation for days after a single dose in humans [1] [5]. The ghrelin arm — ipamorelin — binds GHS-R1a, raises calcium, and triggers a quick GH pulse, while also partly working by opposing somatostatin, the brake the body uses to limit GH. Ipamorelin's signature is its cleanliness: it is the first selective GH secretagogue, releasing GH without raising ACTH or cortisol above GHRH-stimulated levels even at very high multiples of its effective dose, while matching GHRP-6's GH efficacy in swine [2]. That selectivity is why it is preferred over the older, messier GHRPs in the combination.

## Why combine two secretagogues

Combining a GHRH analogue with a GHRP is the oldest validated idea in this space. In normal men, submaximal GHRP doses combined with GHRH stimulated GH release synergistically, the two acting through independent mechanisms [3]; co-activating the two receptors in transfected cells roughly doubled the cAMP signal of GHRH alone [4]. The practical rationale for the CJC-1295 ipamorelin pairing follows directly: a long-acting GHRH background (CJC-1295) keeps the GHRH receptor engaged, while the selective ghrelin-receptor pulse (ipamorelin) adds a clean burst on top — together producing a larger, more physiological-looking GH release than either arm alone. The rationale is well grounded; the specific blend's pulse profile is not characterized in any controlled study.

## The class safety signal

As a class, growth hormone secretagogues carry a consistent and well-described safety signal. A review of the class found the compounds generally well tolerated, with the chief concern being increased blood glucose from decreased insulin sensitivity, and with long-term data on cancer incidence and mortality still needed [6]. Because raising GH also raises IGF-1 — a mitogen — the theoretical oncologic caution applies to any secretagogue strategy, including this one [1]. These are the same cautions detailed, with their mechanisms, on the [CJC-1295 Ipamorelin effects](/effects) page; they belong to the secretagogue category as a whole, not uniquely to one product.

---

A printed-style monograph of the published CJC-1295 and ipamorelin record — every claim attributed to a single-component or synergy study, the fixed blend openly noted as never trialed; no clinic, no prescription, and nothing here dosed or dispensed.